Pemirolast sodium

Drug Profile

Pemirolast sodium

Alternative Names: CRD 007

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Cardoz
  • Developer Cardoz; Karolinska Institute; Karolinska University Hospital; RSPR Pharma; Sahlgrenska University Hospital; University of Amsterdam
  • Class Antiallergics; Antiasthmatics; Nonsteroidal anti-inflammatories; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic asthma; Asthma
  • No development reported Vasculitis

Most Recent Events

  • 28 Apr 2017 Chemical structure information added
  • 24 Feb 2017 RSPR Pharma completes a phase-II trial in Asthma (Adjunctive treatment) in Bulgaria, Denmark, Poland, United Kingdom (NCT02615080)
  • 01 Nov 2016 Phase-II clinical trials in Allergic asthma in Sweden (PO) (NCT03119714)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top